NEW YORK, Nov. 1 (GenomeWeb News) - Genedata has licensed its Expressionist tool to Signature Diagnostics to create gene profiles in colorectal cancer patients, Genedata said today.
Signature Diagnostics will use the Expressionist software to process and analyze Affymetrix GeneChip data from thousands of CRC patients currently receiving treatment, Genedata said. The goal is to identify unique gene-expression signatures that predict the risk of recurrence and response to therapy of individual patients.
Signature Diagnostics, based in Potsdam, Germany, collaborates with clinical partners to improve the clinical development of oncology drugs and develops molecular diagnostics for predicting outcome and drug response in cancer patients.
Additional details for the licensing agreement were not disclosed.